Aadi Bioscience Announces Publication Of Long-Term Efficacy And Safety Data Further Supporting FYARRO For The Treatment Of Malignant PEComa
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience, Inc. (NASDAQ:AADI) announced long-term efficacy and safety results from its Phase 2 AMPECT study of nab-sirolimus for treating malignant PEComa, showing significant survival benefits. The study, published in the Journal of Clinical Oncology, reported a median duration of response of 39.7 months and median survival over 53 months, surpassing historical median survival rates of 16 to 29 months. The confirmed overall response rate was 38.7%, with durable responses and tolerable safety profile.
March 01, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aadi Bioscience's Phase 2 AMPECT study of nab-sirolimus shows significant survival benefits for malignant PEComa, with a median duration of response of 39.7 months and median survival over 53 months.
The publication of long-term efficacy and safety data from the AMPECT study significantly boosts Aadi Bioscience's profile in the oncology field. The results demonstrate a substantial improvement in treatment outcomes for patients with malignant PEComa, a rare and aggressive cancer. This positive data is likely to enhance investor confidence in AADI, potentially leading to an increase in stock price in the short term due to the promising prospects of nab-sirolimus.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100